利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.018 秒)

    PHARMACEUTICAL COMBINATION COMPRISING A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR AND/AN AROMATASE INHIBITOR
    11.
    发明申请
    PHARMACEUTICAL COMBINATION COMPRISING A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR AND/AN AROMATASE INHIBITOR 有权
    包含磷脂酰肌氨酸激酶抑制剂和/或芳香酶抑制剂的药物组合

    公开(公告)号：US20150231124A1

    公开(公告)日：2015-08-20

    申请号：US14429367

    申请日：2013-09-18

    申请人： Michael GOLDBRUNNER ,  Xizhong HUANG

    发明人： Michael Goldbrunner ,  Xizhong Huang

    IPC分类号： A61K31/4439 ,  A61K31/4196 ,  A61K31/5685

    CPC分类号： A61K31/4439 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/445 ,  A61K31/566 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and at least one aromatase inhibitor for the treatment of cancer; the uses of such combinations in the treatment of cancer; and to a method of treating warm-blooded animals including humans suffering cancer by administering to said animal in need of such treatment an effective dose of a 2-carboxamide cycloamino urea derivative compound of formula (I) in combination with at least one aromatase inhibitor.

    摘要翻译： 本发明涉及包含式（I）的2-甲酰胺环氨基脲衍生物化合物和至少一种用于治疗癌症的芳香酶抑制剂的药物组合; 这些组合在治疗癌症中的用途; 以及通过向需要这种治疗的所述动物施用有效剂量的式（I）的2-甲酰胺环氨基脲衍生物化合物与至少一种芳香酶抑制剂组合来治疗包括患有癌症的人的温血动物的方法。

    SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS
    15.
    发明申请
    SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS 有权
    PI3K和MEK-INHIBITORS的协同组合

    公开(公告)号：US20140179744A1

    公开(公告)日：2014-06-26

    申请号：US14240499

    申请日：2012-08-30

    申请人： Fritsch Christine ,  Xizhong Huang ,  Markus Boehm ,  Emmanuelle di Tomaso ,  Jan Cosaert

    发明人： Fritsch Christine ,  Xizhong Huang ,  Markus Boehm ,  Emmanuelle di Tomaso ,  Jan Cosaert

    IPC分类号： A61K31/4439 ,  A61K31/4412 ,  A61K31/4184

    CPC分类号： A61K31/4439 ,  A61K31/4184 ,  A61K31/4412 ,  A61K45/06 ,  A61K2300/00

    摘要： A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

    摘要翻译： 一种药物组合，其包含（a）磷脂酰肌醇3-激酶（PI3K）抑制剂化合物（S） - 吡咯烷-1,2-二羧酸2-酰胺1 - （{4-甲基-5- [2- 2-三氟-1,1-二甲基 - 乙基） - 吡啶-4-基] - 噻唑-2-基} - 酰胺）或其药学上可接受的盐，和（b）至少一种丝裂原活化蛋白激酶（MEK） 抑制剂或药学上可接受的盐，以及任选的至少一种药学上可接受的载体，用于同时，分开或顺序施用; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

    MELK Regulation for the Treatment of Breast Cancer
    17.
    发明申请
    MELK Regulation for the Treatment of Breast Cancer 审中-公开
    MELK治疗乳腺癌的规定

    公开(公告)号：US20170073687A1

    公开(公告)日：2017-03-16

    申请号：US15363823

    申请日：2016-11-29

    申请人： Xizhong Huang ,  Jean J. Zhao ,  Junxia Min ,  Yubao Wang

    发明人： Xizhong Huang ,  Jean J. Zhao ,  Junxia Min ,  Yubao Wang

    IPC分类号： C12N15/113

    CPC分类号： C12N15/1135 ,  A61K31/7088 ,  A61K38/12 ,  C12N9/12 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y207/11001

    摘要： Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. In some aspects, the methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. Methods of treatment for breast cancer and methods of identifying patients having cancer that are likely to benefit from treatment with a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor are also provided.

    摘要翻译： 提供了抑制乳腺癌细胞生长或增殖的方法。 所述方法包括以有效抑制乳腺癌细胞生长或增殖的量向有需要的受试者施用MELK抑制剂，其中乳腺癌细胞为雌激素受体（ER）为阴性。 在一些方面，所述方法包括以有效抑制乳腺癌细胞生长或增殖的量向有需要的受试者施用MELK抑制剂，FoxM1抑制剂或MELK抑制剂和FoxM1抑制剂，其中乳腺癌 细胞是雌激素受体（ER）阴性。 还提供了用于乳腺癌的治疗方法和鉴定可能受益于用MELK抑制剂，FoxM1抑制剂或MELK抑制剂和FoxM1抑制剂治疗的癌症的患者的方法。

    Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and/an aromatase inhibitor
    18.
    发明授权
    Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and/an aromatase inhibitor 有权
    包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合

    公开(公告)号：US09532982B2

    公开(公告)日：2017-01-03

    申请号：US14429367

    申请日：2013-09-18

    申请人： Michael Goldbrunner ,  Xizhong Huang

    发明人： Michael Goldbrunner ,  Xizhong Huang

    IPC分类号： A61K31/4439 ,  A61K31/5685 ,  A61K31/4196

    CPC分类号： A61K31/4439 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/445 ,  A61K31/566 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and at least one aromatase inhibitor for the treatment of cancer; the uses of such combinations in the treatment of cancer; and to a method of treating warm-blooded animals including humans suffering cancer by administering to said animal in need of such treatment an effective dose of a 2-carboxamide cycloamino urea derivative compound of formula (I) in combination with at least one aromatase inhibitor.

    摘要翻译： 本发明涉及包含式（I）的2-甲酰胺环氨基脲衍生物化合物和至少一种用于治疗癌症的芳香酶抑制剂的药物组合; 这些组合在治疗癌症中的用途; 以及通过向需要这种治疗的所述动物施用有效剂量的式（I）的2-甲酰胺环氨基脲衍生物化合物与至少一种芳香酶抑制剂组合来治疗包括患有癌症的人的温血动物的方法。

    Combination of PI3K Inhibitor and C-Met Inhibitor
    20.
    发明申请
    Combination of PI3K Inhibitor and C-Met Inhibitor 审中-公开
    PI3K抑制剂和C-Met抑制剂的组合

    公开(公告)号：US20150216870A1

    公开(公告)日：2015-08-06

    申请号：US14420792

    申请日：2013-08-14

    申请人： Giordano Caponigro ,  Xizhong Huang ,  Joseph Lehar ,  Hui-Qin Wang

    发明人： Giordano Caponigro ,  Xizhong Huang ,  Joseph Lehar ,  Hui-Qin Wang

    IPC分类号： A61K31/53 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/4745

    CPC分类号： A61K31/53 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

    摘要翻译： 本发明涉及药物组合，其包含（a）磷脂酰肌醇3-激酶抑制剂或其药学上可接受的盐，和（b）至少一种c-Met受体酪氨酸激酶抑制剂或其药学上可接受的盐，用于同时，分开或 顺序给药用于治疗增殖性疾病，特别是c-Met依赖性增殖性疾病; 包含这种组合的药物组合物; 治疗具有增殖性疾病的受试者的方法，包括向有需要的受试者施用所述组合; 使用这种组合治疗增生性疾病; 以及包括这种组合的商业包装。